Čistjakovs, MaksimsSultanova, AlinaJermakova, OlgaČapenko, SvetlanaLesiņa-Korne, BaibaRozentāls, RafailsMurovska, ModraZiediņa, Ieva2021-06-212021-06-212016-08-01Čistjakovs, M, Sultanova, A, Jermakova, O, Čapenko, S, Lesiņa-Korne, B, Rozentāls, R, Murovska, M & Ziediņa, I 2016, 'High-Risk Human Papillomavirus Infection in Latvian Male Kidney Transplant Recipients', Proceedings of the Latvian Academy of Sciences, Section B: Natural, Exact, and Applied Sciences, vol. 70, no. 4, pp. 193-197. https://doi.org/10.1515/prolas-2016-00301407-009Xhttps://dspace.rsu.lv/jspui/handle/123456789/5334Publisher Copyright: © 2016 by Maksims Cistjakovs.Kidney transplant recipients have higher incidence of human papillomavirus (HPV)-related malignancies, but studies on the natural history of HPV infection are insufficient, especially regarding in male recipients. The aim of this study was to evaluate the course of high-risk HPV (HR-HPV) infection after kidney allograft transplantation in male recipients: to estimate frequency and activity of HR-HPV infection under immune system suppression. Twenty male renal recipients (age 20-68) were enrolled in this investigation and examined in dynamics. Peripheral EDTA-blood samples and urine samples were collected from each patient 2 weeks, 6 months and 12 months after transplantation. Polymerase chain reaction (PCR) with consensus primers was used for initial detection of high range HPV types, a commercial qPCR kit for detection of HR-HPV load in urine samples and ELISA for detection of serum IgG class antibodies to HR-HPV L1-capsid protein. Overall, combining molecular (HR-HPV genomic sequences detected by real-time PCR) and serological studies (IgG class antibodies to HR-HPV L1-capsids' protein), high frequency of HRHPV infection among male kidney transplant recipients (9/20; 45%) was showed. However, the majority of HR-HPV positive recipients (7/9; 78%) showed signs of infection clearance. It means that, despite the applied immune suppressive therapy, the host's immune system is capable of dealing with HR-HPV infection up to the 12th month after transplantation. However, the sample size should be increased to enable through statistical analysis before final conclusions are made.572769enginfo:eu-repo/semantics/openAccessHR-HPVkidney transplant recipients3.2 Clinical medicine3.3 Health sciences1.1. Scientific article indexed in Web of Science and/or Scopus databaseGeneral/dk/atira/pure/researchoutput/researchoutputtypes/contributiontojournal/article10.1515/prolas-2016-0030http://www.scopus.com/inward/record.url?scp=84983420831&partnerID=8YFLogxK